Brokerages Set Pharvaris N.V. (NASDAQ:PHVS) PT at $37.57

Pharvaris N.V. (NASDAQ:PHVS) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $40.5556.

Several equities analysts have recently weighed in on the stock. Guggenheim increased their price objective on shares of Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday. Morgan Stanley raised their price objective on shares of Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, November 19th. Wedbush lifted their price target on Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Finally, Leerink Partners set a $38.00 price target on Pharvaris in a research note on Wednesday.

Hedge Funds Weigh In On Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of PHVS. Woodline Partners LP bought a new position in Pharvaris during the third quarter worth about $2,495,000. venBio Partners LLC lifted its position in Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after purchasing an additional 350,000 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Pharvaris in the 3rd quarter valued at approximately $3,119,000. Polar Capital Holdings Plc acquired a new stake in shares of Pharvaris during the 3rd quarter worth approximately $6,604,000. Finally, Public Employees Retirement System of Ohio increased its stake in Pharvaris by 39.3% in the third quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock valued at $156,000 after acquiring an additional 1,769 shares during the last quarter.

Pharvaris Trading Down 4.6%

Shares of NASDAQ PHVS opened at $26.42 on Wednesday. The company has a market capitalization of $1.38 billion, a P/E ratio of -8.23 and a beta of -2.80. Pharvaris has a 12 month low of $11.51 and a 12 month high of $29.80. The stock has a 50 day moving average of $23.81 and a 200-day moving average of $21.58.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.08. Analysts predict that Pharvaris will post -2.71 EPS for the current fiscal year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.